Translate this page to:
Choose Language…
In JoVE (4)
- Combining Transcranial Magnetic Stimulation and fMRI to Examine the Default Mode Network
- TMS: Using the Theta-Burst Protocol to Explore Mechasnism of Plasticity in Individuals with Fragile X Syndrome and Autism
- State-Dependency Effects on TMS: A Look at Motive Phosphene Behavior
- The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression
Other Publications (2)
Articles by Jared C. Horvath in JoVE
JoVE Neuroscience
Combining Transcranial Magnetic Stimulation and fMRI to Examine the Default Mode Network
Berenson-Allen Center for Noninvasive Brain Stimulation, Beth Israel Deaconess Medical Center
In this article, we examine the methodology and considerations relevant to the combination of TMS and fMRI to examine the effects of brain stimulation on the default network.
JoVE Neuroscience
TMS: Using the Theta-Burst Protocol to Explore Mechasnism of Plasticity in Individuals with Fragile X Syndrome and Autism
Berenson-Allen Center for Noninvasive Brain Stimulation, Beth Israel Deaconess Medical Center
In this article, we examine the effects of Theta-Burst TMS stimulation on cortical plasticity in individuals suffering from Fragile X syndrome and individuals on the autistic spectrum.
JoVE Neuroscience
State-Dependency Effects on TMS: A Look at Motive Phosphene Behavior
1Berenson-Allen Center for Noninvasive Brain Stimulation, Beth Israel Deaconess Medical Center, 2Brain Research Unit, Low Temperature Laboratory and Advanced magnetic Imaging Center, Aalto University School of Science and Technology
In this article, we examine the effects of visually relevant state dependency on TMS induced motive phosphenic presentations.
JoVE Neuroscience
The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression
1Berenson-Allen Center for Noninvasive Brain Stimulation, Beth Israel Deaconess Medical Center, 2Neuronetics, Inc.
In this article, we examine the methodology and considerations relevant to the FDA approved depression treatment protocol using the Neuronetics NeuroStar TMS device.
Other articles by Jared C. Horvath on PubMed
Transcranial Magnetic Stimulation: a Historical Evaluation and Future Prognosis of Therapeutically Relevant Ethical Concerns
Transcranial Magnetic Stimulation (TMS) is a non-invasive neurostimulatory and neuromodulatory technique increasingly used in clinical and research practices around the world. Historically, the ethical considerations guiding the therapeutic practice of TMS were largely concerned with aspects of subject safety in clinical trials. While safety remains of paramount importance, the recent US Food and Drug Administration approval of the Neuronetics NeuroStar TMS device for the treatment of specific medication-resistant depression has raised a number of additional ethical concerns, including marketing, off-label use and technician certification. This article provides an overview of the history of TMS and highlights the ethical questions that are likely arise as the therapeutic use of TMS continues to expand.
Characterizing Brain Cortical Plasticity and Network Dynamics Across the Age-span in Health and Disease with TMS-EEG and TMS-fMRI
Brain plasticity can be conceptualized as nature's invention to overcome limitations of the genome and adapt to a rapidly changing environment. As such, plasticity is an intrinsic property of the brain across the lifespan. However, mechanisms of plasticity may vary with age. The combination of transcranial magnetic stimulation (TMS) with electroencephalography (EEG) or functional magnetic resonance imaging (fMRI) enables clinicians and researchers to directly study local and network cortical plasticity, in humans in vivo, and characterize their changes across the age-span. Parallel, translational studies in animals can provide mechanistic insights. Here, we argue that, for each individual, the efficiency of neuronal plasticity declines throughout the age-span and may do so more or less prominently depending on variable 'starting-points' and different 'slopes of change' defined by genetic, biological, and environmental factors. Furthermore, aberrant, excessive, insufficient, or mistimed plasticity may represent the proximal pathogenic cause of neurodevelopmental and neurodegenerative disorders such as autism spectrum disorders or Alzheimer's disease.
